Mónica M Calderón1,2, Scott R Penzak1, Alice K Pau3, Parag Kumar1, Maryellen McManus2, Raul M Alfaro1, Joseph A Kovacs4. 1. Pharmacy Department, National Institutes of Health (NIH) Clinical Center, Bethesda. 2. Leidos Biomedical Research, Inc, National Cancer Institute at Frederick. 3. National Institute of Allergy and Infectious Diseases, NIH. 4. Critical Care Medicine Department, NIH Clinical Center, Bethesda, Maryland.
Abstract
BACKGROUND: The current study was conducted to determine if efavirenz (EFV) or atazanavir/ritonavir (ATV/r)-based combination antiretroviral therapy (cART) impacted steady-state atovaquone plasma concentrations in human immunodeficiency virus (HIV)-infected patients receiving treatment doses of atovaquone. METHODS:Thirty HIV-infected volunteers were recruited, 10 taking no cART and 10 each takingcART that included EFV or ATV/r. Subjects were randomly assigned to atovaquone 750 mg twice daily (BID) for 14 days followed by atovaquone 1500 mg BID for 14 days, or vice-versa, with a washout period in between. On day 14 of each phase, blood was sampled for pharmacokinetic studies, and the area under the concentration-time curve (AUCτ) and average concentration (C avg) were calculated and compared using an unpaired t test. RESULTS:Twenty-nine subjects completed both dosing cohorts. Subjects receiving EFV-based cART had 47% and 44% lower atovaquone AUCτ than subjects not receiving cART at atovaquone doses of 750 mg BID and 1500 mg BID, respectively (P≤ .01). Only 5 of 10 subjects receiving EFV-based cART plusatovaquone 750 mg BID had an atovaquone C avg>15 µg/mL, which has previously been associated with successful treatment of Pneumocystis jirovecipneumonia. AUCτ and Cavg did not significantly differ for concurrent ATV/r for 750 mg BID or 1500 mg BID when compared to the group not receiving cART. Nine of 10 subjects not receiving cART, 8 of 10 subjects receiving ATV/r, and 2 of 10 subjects receivingEFV in combination with atovaquone 750 mg BID achieved an atovaquone C avg>18.5 µg/mL, a concentration that has previously been associated with successful treatment of Toxoplasmaencephalitis (TE). CONCLUSIONS: These data suggest that the currently recommended dose of atovaquone 750 mg BID for treatment of mild to moderate PCP may not be adequate in patients receiving concurrent EFV. Furthermore, doses lower than the currently recommended dose of 1500 mg BID may achieve plasma concentrations adequate to treat TE in HIV-infected patients not receiving EFV. CLINICAL TRIALS REGISTRATION: NCT01479361. Published by Oxford University Press for the Infectious Diseases Society of America 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US.
RCT Entities:
BACKGROUND: The current study was conducted to determine if efavirenz (EFV) or atazanavir/ritonavir (ATV/r)-based combination antiretroviral therapy (cART) impacted steady-state atovaquone plasma concentrations in human immunodeficiency virus (HIV)-infectedpatients receiving treatment doses of atovaquone. METHODS: Thirty HIV-infected volunteers were recruited, 10 taking no cART and 10 each taking cART that included EFV or ATV/r. Subjects were randomly assigned to atovaquone 750 mg twice daily (BID) for 14 days followed by atovaquone 1500 mg BID for 14 days, or vice-versa, with a washout period in between. On day 14 of each phase, blood was sampled for pharmacokinetic studies, and the area under the concentration-time curve (AUCτ) and average concentration (C avg) were calculated and compared using an unpaired t test. RESULTS: Twenty-nine subjects completed both dosing cohorts. Subjects receiving EFV-based cART had 47% and 44% lower atovaquone AUCτ than subjects not receiving cART at atovaquone doses of 750 mg BID and 1500 mg BID, respectively (P≤ .01). Only 5 of 10 subjects receiving EFV-based cART plus atovaquone 750 mg BID had an atovaquone C avg>15 µg/mL, which has previously been associated with successful treatment of Pneumocystis jirovecipneumonia. AUCτ and Cavg did not significantly differ for concurrent ATV/r for 750 mg BID or 1500 mg BID when compared to the group not receiving cART. Nine of 10 subjects not receiving cART, 8 of 10 subjects receiving ATV/r, and 2 of 10 subjects receiving EFV in combination with atovaquone 750 mg BID achieved an atovaquone C avg>18.5 µg/mL, a concentration that has previously been associated with successful treatment of Toxoplasmaencephalitis (TE). CONCLUSIONS: These data suggest that the currently recommended dose of atovaquone 750 mg BID for treatment of mild to moderate PCP may not be adequate in patients receiving concurrent EFV. Furthermore, doses lower than the currently recommended dose of 1500 mg BID may achieve plasma concentrations adequate to treat TE in HIV-infectedpatients not receiving EFV. CLINICAL TRIALS REGISTRATION: NCT01479361. Published by Oxford University Press for the Infectious Diseases Society of America 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Entities:
Keywords:
Pneumocystis jiroveci pneumonia; atovaquone; drug interaction; efavirenz; toxoplasma encephalitis
Authors: Keith Chirgwin; Richard Hafner; Catherine Leport; Jack Remington; Janet Andersen; Elizabeth M Bosler; Clemente Roque; Natasa Rajicic; Vincent McAuliffe; Philippe Morlat; D T Jayaweera; Jean-Louis Vilde; Benjamin J Luft Journal: Clin Infect Dis Date: 2002-05-01 Impact factor: 9.079
Authors: Donglu Zhang; Theodore J Chando; Donald W Everett; Christopher J Patten; Shangara S Dehal; W Griffith Humphreys Journal: Drug Metab Dispos Date: 2005-08-23 Impact factor: 3.922
Authors: Matthijs van Luin; Marchina E Van der Ende; Clemens Richter; Mirjam Visser; Diari Faraj; Andre Van der Ven; Luc Gelinck; Frank Kroon; Ferdinand W Wit; Ron H N Van Schaik; Paul F M Kuks; David M Burger Journal: AIDS Date: 2010-05-15 Impact factor: 4.177
Authors: D Ouellet; A Hsu; J Qian; C S Locke; C J Eason; J H Cavanaugh; J M Leonard; G R Granneman Journal: Br J Clin Pharmacol Date: 1998-08 Impact factor: 4.335
Authors: Manon J van der Lee; Lara Dawood; Hadewych J M ter Hofstede; Marga J A de Graaff-Teulen; Eleonora W J van Ewijk-Beneken Kolmer; Nurcan Caliskan-Yassen; Peter P Koopmans; David M Burger Journal: Clin Pharmacol Ther Date: 2006-08 Impact factor: 6.875
Authors: W Hughes; G Leoung; F Kramer; S A Bozzette; S Safrin; P Frame; N Clumeck; H Masur; D Lancaster; C Chan Journal: N Engl J Med Date: 1993-05-27 Impact factor: 91.245
Authors: D M Burger; A Huisman; N Van Ewijk; H Neisingh; P Van Uden; G A Rongen; P Koopmans; R J Bertz Journal: Clin Pharmacol Ther Date: 2008-06-04 Impact factor: 6.875
Authors: Mamta K Jain; James A De Lemos; Darren K McGuire; Colby Ayers; Jennifer L Eitson; Claudia L Sanchez; Dena Kamel; Jessica A Meisner; Emilia V Thomas; Anita A Hegde; Satish Mocherla; Joslyn K Strebe; Xilong Li; Noelle S Williams; Chao Xing; Mahmoud S Ahmed; Ping Wang; Hesham A Sadek; John W Schoggins Journal: Front Pharmacol Date: 2022-09-30 Impact factor: 5.988
Authors: Kay Seden; Sara Gibbons; Catia Marzolini; Jonathan M Schapiro; David M Burger; David J Back; Saye H Khoo Journal: PLoS One Date: 2017-03-23 Impact factor: 3.240